Department of Radiological Sciences, University of Rome Sapienza, Rome 00159, Italy.
Br J Radiol. 2011 Aug;84(1004):698-708. doi: 10.1259/bjr/21539234.
The aim of this study was to compare the intraindividual effects of contrast material with two different iodine concentrations on the conspicuity of hepatocellular carcinoma (HCC) and vascular and hepatic contrast enhancement during multiphasic, 64-section multidetector row CT (MDCT) in patients with cirrhosis using two contrast medium injection techniques.
Patients were randomly assigned to one of two groups with an equal iodine dose but different contrast material injection techniques: scheme A, fixed injection duration (25 s), and scheme B, fixed injection flow rate (4 ml s(-1)). For each group, patients were randomised to receive both moderate-concentration contrast medium (MCCM) and high-concentration contrast medium (HCCM) during two CT examinations within 3 months. Enhancement of the aorta, liver and portal vein and the tumour-to-liver contrast-to-noise ratio (CNR) were compared between MCCM and HCCM.
30 patients (mean age 59 years; range 45-80 years; 16 patients in scheme A and 14 in scheme B) with a total of 31 confirmed HCC nodules were prospectively enrolled. For scheme B, the mean contrast enhancement of the aorta and tumour-to-liver CNR were significantly higher with HCCM than with MCCM during the hepatic arterial phase (+350.5 HU vs +301.1 HU, p = 0.001, and +7.5 HU vs +5.5 HU, p = 0.004). For both groups, there was no significant difference between MCCM and HCCM for all other comparisons.
For a constant injection flow rate, HCCM significantly improves the conspicuity of HCC lesions and aortic enhancement during the hepatic arterial phase on 64-section MDCT in patients with cirrhosis.
本研究旨在比较两种不同碘浓度的对比剂在肝硬化患者 64 层多排 CT(MDCT)多期扫描中对肝癌(HCC)及血管和肝实质增强的个体内效应,采用两种对比剂注射技术。
患者被随机分为两组,每组碘剂量相等,但对比剂注射技术不同:方案 A,固定注射时间(25 s);方案 B,固定注射流率(4 ml/s)。对于每组,患者在 3 个月内的两次 CT 检查中随机接受中浓度对比剂(MCCM)和高浓度对比剂(HCCM)。比较 MCCM 和 HCCM 时主动脉、肝和门静脉的增强以及肿瘤-肝对比噪声比(CNR)。
前瞻性纳入 30 例(平均年龄 59 岁;范围 45-80 岁;方案 A 16 例,方案 B 14 例)共 31 个确诊 HCC 结节患者。对于方案 B,HCCM 时肝动脉期主动脉和肿瘤-肝 CNR 的平均对比增强明显高于 MCCM(+350.5 HU 比+301.1 HU,p=0.001;+7.5 HU 比+5.5 HU,p=0.004)。对于两组,其他所有比较中,MCCM 和 HCCM 之间均无显著差异。
对于恒定的注射流率,HCCM 可显著提高肝硬化患者 64 层 MDCT 肝动脉期 HCC 病变和主动脉的显示效果。